Could a common diabetes pill ease heart failure from rare protein disease?
NCT ID NCT05795400
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This pilot study tested the drug dapagliflozin (a diabetes medicine) in 50 adults with heart failure due to amyloid cardiomyopathy, a condition where abnormal proteins stiffen the heart. The goal was to see if the drug improves quality of life, walking ability, and heart stress markers. Researchers measured changes in a heart failure questionnaire, a 6-minute walk test, and blood levels of NT-proBNP. The study is completed, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow, 121552, Russia
Conditions
Explore the condition pages connected to this study.